文献速递淋巴瘤

中期PET对一线R-CHOP治疗的套细胞淋巴瘤患者的预后影响

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
PubMed 文献 · Br J Haematol · 2019-11-16

该回顾性研究纳入89例接受一线R-CHOP的晚期套细胞淋巴瘤患者,评估中期PET(iPET)和治疗结束PET(ePET)与生存的相关性。iPET是独立预后因素,需前瞻性试验验证iPET指导策略。

要点

  • 代谢反应顺序早期、延迟、丢失、从未反应者生存依次变差。
  • iPET为独立预后因素,支持前瞻性iPET指导治疗试验。

核心结论

  • iPET对接受一线R-CHOP的MCL患者具有预后价值,是生存的独立预测因素。

研究设计与样本

  • 回顾性评估89例连续晚期MCL患者,均接受一线R-CHOP治疗。

主要发现

  • OS和PFS按早期代谢反应者、延迟反应者、代谢反应丢失者、从未代谢反应者顺序更优。
  • 在不适合auto-HSCT组中,早期代谢反应者OS和PFS显著更优。

临床怎么用

  • iPET可作为MCL患者一线R-CHOP治疗的预后评估工具,指导风险分层。

局限性

  • 回顾性研究设计,样本量有限,iPET指导治疗策略需前瞻性临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although 18 F-fluorodeoxyglucose positron emission tomography (18 F-FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end-of-treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five-year overall survival (OS) [hazard ratio (HR) 7·84, P < 0·0001] and poor five-year progression-free survival (PFS) (HR 3·34, P < 0·0001). OS and PFS were more favourable in the order early metabolic responder (iPETneg → ePETneg ), delayed responder (iPETpos → ePETneg ), loss-metabolic responder (iPETneg → ePETpos ), and never-metabolic responder (iPETpos → ePETpos ). In the autologous haematopoietic stem cell transplantation (auto-HSCT)-fit subgroup, OS was more favourable in the order early metabolic responders, delayed metabolic responders, and non-metabolic responders, with a marginal trend toward statistical significance (HR 3·41, P = 0·051), and PFS was significantly superior in early metabolic responders (HR 4·43, P = 0·002). In a group that was ineligible for auto-HSCT, OS and PFS were significantly superior in early metabolic responders. Our results suggested that iPET is of prognostic value and an independent predictor of survival in MCL patients receiving frontline R-CHOP. Therefore, prospective clinical trials of iPET-guided treatment strategies for these patients are warranted.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jeon YW, O JH, Park KS, et al. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. Br J Haematol. 2019. PMID: 31733125. doi:10.1111/bjh.16257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。